Moderna’s COVID-19 Vaccine To Get Real-Time Data Assessment By US FDA
Executive Summary
Commissioner Hahn says FDA will see data as it is compiled to speed review; enrollment criteria raises some eyebrows since Moderna plans to exclude patients with known history of SARS-CoV-2 infection from Phase III. The agency’s guidance on COVID-19 vaccine trials says that such exclusions are not necessary since screening is unlikely when a product would be delivered post-market.
You may also be interested in...
After Pandemic, US FDA Commissioner Wants To Continue ‘Rolling Review’ Offered To COVID-19 Products
Stephen Hahn also said the expedited approval process could be even more efficient.
Taking The ‘O’ Out Of RTOR: US FDA’s Real-Time Review Primed For Expansion Beyond Oncology
Technology modernization efforts, the expansion of cloud-based submission capabilities, and the ongoing COVID-19 pandemic could serve as catalysts to broaden FDA’s Real-Time Oncology Review program beyond cancer therapeutics, Pfizer exec Richard Jahn says.
Could A COVID-19 Vaccine Gain EUA Without Sponsor Cooperation?
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: